Skip to main content
. Author manuscript; available in PMC: 2016 Mar 8.
Published in final edited form as: Exp Neurol. 2007 Dec 23;210(2):602–607. doi: 10.1016/j.expneurol.2007.12.008

Figure 4. Neuroprotective effects of Tat-Bcl-xL in a rat model of status epilepticus.

Figure 4

Either 0.03 μg Tat-MYC or Tat-Bcl-xL was infused unilaterally in the dentate gyrus of rats (six each), 30-minutes before infusion of 0.06 μg KA. The control, contralateral hemisphere was infused with KA alone. Vehicle was injected into a second group of animals as a measure of intact CA3 (No KA). ***p < 0.001, n = 6/group.